Interaction between red yeast rice and CYP450 enzymes/P-glycoprotein and its implication for the clinical pharmacokinetics of lovastatin

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Chen, Chia Hao ^a   Uang, Yow Shieng ^b   Wang, Shang Ta ^a   Yang, Jyh Chin ^c   Lin, Chun Jung ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; CHOLESTIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; GEMFIBROZIL; LIPOCOL FORTE; LOVASTATIN ACID; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN; NIFEDIPINE; UNCLASSIFIED DRUG; XUEZHIKANG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG POTENCY; ENZYME INHIBITION; EVENING DOSAGE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MORNING DOSAGE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84871447117     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/127043     Document Type: Article

References (45)

1. Lewington S., Whitlock G., Clarke R., Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. The Lancet 2007 370 9602 1829 1839 10.1016/S0140-6736(07)61778-4 (Pubitemid 350180032)
2. Heber D., Yip I., Ashley J. M., Elashoff D. A., Elashoff R. M., Go V. L. W., Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. American Journal of Clinical Nutrition 1999 69 2 231 236 2-s2.0-0032898925 (Pubitemid 29065544)
3. Lin C. C., Li T. C., Lai M. M., Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. European Journal of Endocrinology 2005 153 5 679 686 2-s2.0-27944482535 10.1530/eje.1.02012 (Pubitemid 41672414)
4. Liu J., Zhang J., Shi Y., Grimsgaard S., Alraek T., Fonnebo V., Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese Medicine 2006 1, article 4 2-s2.0-34250741897 10.1186/1749-8546-1-4
5. Huang C. F., Li T. C., Lin C. C., Liu C. S., Shih H. C., Lai M. M., Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. European Journal of Cardiovascular Prevention and Rehabilitation 2007 14 3 438 440 2-s2.0-34250620912 10.1097/HJR. 0b013e32801da137 (Pubitemid 46945569)
6. Zhao S. P., Lu Z. L., Du B. M., Chen Z., Wu Y. F., Yu X. H., Zhao Y. C., Liu L., Ye H. J., Wu Z. H., Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China Coronary Secondary Prevention Study (CCSPS). Journal of Cardiovascular Pharmacology 2007 49 2 81 84 2-s2.0-33847223472 10.1097/FJC.0b013e31802d3a58
7. Lu Z., Kou W., Du B., Wu Y., Zhao S., Brusco O. A., Morgan J. M., Capuzzi D. M., Effect of xuezhikang, an extract from red yeast Chinese rice, on coronary events in a chinese population with previous myocardial infarction. American Journal of Cardiology 2008 101 12 1689 1693 2-s2.0-44749084870 10.1016/j.amjcard.2008.02.056
8. Klimek M., Wang S., Ogunkanmi A., Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P and T 2009 34 6 313 327 2-s2.0-67650564624
9. Shang Q., Liu Z., Chen K., Xu H., Liu J., A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evidence-Based Complementary and Alternative Medicine 2012 2012 18 636547 10.1155/2012/636547
10. Becker D. J., Gordon R. Y., Morris P. B., Yorko J., Gordon Y. J., Li M., Iqbal N., Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clinic Proceedings 2008 83 7 758 764 2-s2.0-46749098263 10.4065/83.7.758 (Pubitemid 351948689)
11. Becker D. J., Gordon R. Y., Halbert S. C., French B., Morris P. B., Rader D. J., Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Annals of Internal Medicine 2009 150 12 830 839 2-s2.0-67249153214
12. Gordon R. Y., Cooperman T., Obermeyer W., Becker D. J., Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Archives of Internal Medicine 2010 170 19 1722 1727 2-s2.0-78049264831 10.1001/archinternmed.2010.382
13. Alberts A. W., Chen J., Kuron G., Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proceedings of the National Academy of Sciences of the United States of America 1980 77 7 3957 3961 2-s2.0-0018939225 (Pubitemid 10015499)
14. Wang R. W., Kari P. H., Lu A. Y. H., Thomas P. E., Guengerich F. P., Vyas K. P., Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Archives of Biochemistry and Biophysics 1991 290 2 355 361 2-s2.0-0025944905 10.1016/0003-9861(91)90551-S
15. Chen C., Mireles R. J., Campbell S. D., Lin J., Mills J. B., Xu J. J., Smolarek T. A., Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metabolism and Disposition 2005 33 4 537 546 2-s2.0-15344341734 10.1124/dmd.104.002477 (Pubitemid 40393197)
16. Halbert S. C., French B., Gordon R. Y., Farrar J. T., Schmitz K., Morris P. B., Thompson P. D., Rader D. J., Becker D. J., Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. American Journal of Cardiology 2010 105 2 198 204 2-s2.0-73149101073 10.1016/j.amjcard.2009.08.672
17. Venero C. V., Venero J. V., Wortham D. C., Thompson P. D., Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. American Journal of Cardiology 2010 105 5 664 666 2-s2.0-76849117367 10.1016/j.amjcard. 2009.10.045
18. Prasad G. V. R., Wong T., Meliton G., Bhaloo S., Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002 74 8 1200 1201 2-s2.0-0037184309 (Pubitemid 35216122)
19. Smith D. J., Olive K. E., Chinese red rice-induced myopathy. Southern Medical Journal 2003 96 12 1265 1267 2-s2.0-0345867160 10.1097/01.SMJ. 0000100117.79718.DC (Pubitemid 38090587)
20. Mueller P. S., Symptomatic myopathy due to red yeast rice. Annals of Internal Medicine 2006 145 6 474 475 2-s2.0-33749184642 (Pubitemid 46768586)
21. Roselle H., Ekatan A., Tzeng J., Sapienza M., Kocher J., Symptomatic hepatitis associated with the use of herbal red yeast rice. Annals of Internal Medicine 2008 149 7 516 517 2-s2.0-53749089337
22. Stubbs R. J., Schwartz M., Bayne W. F., Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography. Journal of Chromatography 1986 383 2 438 443 2-s2.0-0022859501 (Pubitemid 17224924)
23. Walsky R. L., Obach R. S., Validated assays for human cytochrome P450 activities. Drug Metabolism and Disposition 2004 32 6 647 660 2-s2.0-2442690439 10.1124/dmd.32.6.647 (Pubitemid 38668158)
24. Yao M., Zhu M., Sinz M. W., Zhang H., Humphreys W. G., Rodrigues A. D., Dai R., Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. Journal of Pharmaceutical and Biomedical Analysis 2007 44 1 211 223 2-s2.0-34047252007 10.1016/j.jpba.2007.02.034 (Pubitemid 46551606)
25. Rautio J., Humphreys J. E., Webster L. O., Balakrishnan A., Keogh J. P., Kunta J. R., Serabjit-Singh C. J., Polli J. W., In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metabolism and Disposition 2006 34 5 786 792 2-s2.0-33645805657 10.1124/dmd.105.008615
26. Chen C. H., Hsu H. J., Huang Y. J., Lin C. J., Interaction of flavonoids and intestinal facilitated glucose transporters. Planta Medica 2007 73 4 348 354 2-s2.0-34250336160 10.1055/s-2007-967172 (Pubitemid 46910417)
27. Ohno Y., Hisaka A., Suzuki H., General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clinical Pharmacokinetics 2007 46 8 681 696 2-s2.0-34547641389 10.2165/00003088-200746080-00005 (Pubitemid 47204854)
28. Cesari M., Pessina A. C., Combined antihypertensive and lipid-Lowering treatment. Current Hypertension Reports 2004 6 4 300 306 2-s2.0-4344714594 (Pubitemid 39144655)
29. Kyrklund C., Backman J. T., Kivistö K. T., Neuvonen M., Laitila J., Neuvonen P. J., Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clinical Pharmacology and Therapeutics 2001 69 5 340 345 2-s2.0-0035337643 10.1067/mcp.2001.115542 (Pubitemid 32477075)
30. Neuvonen P. J., Niemi M., Backman J. T., Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics 2006 80 6 565 581 2-s2.0-33845420011 10.1016/j.clpt.2006.09.003 (Pubitemid 44908269)
31. Neuvonen P. J., Backman J. T., Niemi M., Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clinical Pharmacokinetics 2008 47 7 463 474 2-s2.0-45549091043 10.2165/00003088-200847070-00003 (Pubitemid 351861958)
32. Bjornsson T. D., Callaghan J. T., Einolf H. J., Fischer V., Gan L., Grimm S., Kao J., King S. P., Miwa G., Ni L., Kumar G., McLeod J., Obach S. R., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J. T., Tweedie D., Vega J. M., Walsh J., Wrighton S. A., The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. Journal of Clinical Pharmacology 2003 43 5 443 469 2-s2.0-0142131213 (Pubitemid 36506147)
33. Zhang L., Zhang Y., Strong J. M., Reynolds K. S., Huang S. M., A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008 38 7-8 709 724 2-s2.0-48749084803 10.1080/00498250802017715
34. US Food and Drug Administration,. Guidance for industry on drug interaction studies- study design, data analysis, implications for dosing, and labeling recommendations, 2012, http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
35. Os I., Bratland B., Dahlof B., Gisholt K., Syvertsen J. O., Tretli S., Effect and tolerability of combining lovastatin with nifedipine or lisinopril. American Journal of Hypertension 1993 6 8 688 692 2-s2.0-0027316940 (Pubitemid 23268601)
36. Fenner K. S., Troutman M. D., Kempshall S., Cook J. A., Ware J. A., Smith D. A., Lee C. A., Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clinical Pharmacology and Therapeutics 2009 85 2 173 181 2-s2.0-58549088199 10.1038/clpt.2008.195
37. 50 criteria in the P-gp decision tree. The Journal of Clinical Pharmacology. In press 10.1177/0091270011436344
38. Omar M. A., Wilson J. P., FDA adverse event reports on statin-associated rhabdomyolysis. Annals of Pharmacotherapy 2002 36 2 288 295 2-s2.0-0036163750 (Pubitemid 34126824)
39. Prueksaritanont T., Ma B., Yu N., The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. British Journal of Clinical Pharmacology 2003 56 1 120 124 2-s2.0-0038336614 10.1046/j.1365-2125.2003.01833.x (Pubitemid 36886497)
40. Shitara Y., Hirano M., Sato H., Sugiyama Y., Gemfibrozil and its glucoronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. Journal of Pharmacology and Experimental Therapeutics 2004 311 1 228 236 2-s2.0-4644301418 10.1124/jpet.104.068536 (Pubitemid 39287802)
41. Fuhr U., Müller-Peltzer H., Kern R., Lopez-Rojas P., Jünemann M., Harder S., Staib H. A., Effects of grapefruit juice and smoking on verapamil concentrations in steady state. European Journal of Clinical Pharmacology 2002 58 1 45 53 2-s2.0-0036220634 10.1007/s00228-002-0436-7 (Pubitemid 34327993)
42. Kazui M., Nishiya Y., Ishizuka T., Hagihara K., Farid N. A., Okazaki O., Ikeda T., Kurihara A., Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metabolism and Disposition 2010 38 1 92 99 2-s2.0-73149119363 10.1124/dmd.109.029132
43. Chen C. H., Yang J. C., Uang Y. S., Lin C. J., Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharmaceutics & Drug Disposition 2012 33 5 278 283 10.1002/bdd.1795
44. Mega J. L., Close S. L., Wiviott S. D., Shen L., Hockett R. D., Brandt J. T., Walker J. R., Antman E. M., Macias W., Braunwald E., Sabatine M. S., Cytochrome P-450 polymorphisms and response to clopidogrel. New England Journal of Medicine 2009 360 4 354 362 2-s2.0-58749094444 10.1056/NEJMoa0809171
45. Yang J. C., Lin C. J., CYP2C19 genotypes in the pharmacokinetics/ pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opinion on Drug Metabolism and Toxicology 2010 6 1 29 41 2-s2.0-72949117415 10.1517/17425250903386251